Posted: Wednesday, April 26, 2023
William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the monarchE trial. When the study was first conducted, findings suggested there was a benefit to adding abemaciclib as a component of adjuvant therapy for patients with high-risk breast cancer. With longer follow-up, the data have become more compelling, Dr. Gradishar says, showing a sustained and expanded benefit to the use of this CDK4/6 inhibitor. He talks about how PARP inhibitors could be integrated into this treatment.